Bacopa monnieri
Cognitive · Ayurvedic adaptogen
Tier B+
Bottom line
Read Off Label grades Bacopa monnieri as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.
Effects are delayed — typically 8-12 weeks to see measurable cognitive benefits.
Studied, labeled, or reported-use context: 300-600 mg/day standardized to 45-55% bacosides, minimum 8-12 weeks — OTC; not individualized guidance.
If you were testing this on yourself
Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.
Can you undo it?
Reverses on stopping
Reversible; GI upset, the common complaint, stops with the dose.
Can you tell if it worked?
Readable — 8–12 weeks minimum — one of the slowest on this list
A repeatable memory task. Bacopa acts on memory acquisition, so a general "feel sharper" check will miss it.
What would fool you Almost everyone quits before the effect window. Practice effects on any repeated cognitive test are large and will look like improvement, so you need a task with parallel forms or a long gap between attempts.
What the evidence says
Effects are delayed — typically 8-12 weeks to see measurable cognitive benefits. Kongkeaw 2014 meta-analysis confirmed improvements in free recall. Coadministration with fat increases absorption. Some GI side effects common in first weeks.
Mechanism
Bacosides A&B modulate cholinergic, serotonergic, GABAergic systems; antioxidant, dendritic proliferation; slow-onset cognitive enhancer requiring chronic dosing
Studied, labeled, or reported dose & route
300-600 mg/day standardized to 45-55% bacosides, minimum 8-12 weeks
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
- PubMed · PMID 24252493
- PubMed · PMID 24533867
- pmc.ncbi.nlm.nih.gov
- PubMed · PMID 36014874
- PubMed · PMID 41901106
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Bacopa monnieri's effects?
- Read Off Label rates the evidence for Bacopa monnieri as Moderate and the benefit magnitude as med, producing an overall grade of B+ (7.1/10). Effects are delayed — typically 8-12 weeks to see measurable cognitive benefits.
- What safety findings are reported for Bacopa monnieri?
- Bacopa monnieri has a low risk profile in the database. Low (GI upset common; rare sedation) Legal status: OTC.
- What doses or routes are reported for Bacopa monnieri?
- 300-600 mg/day standardized to 45-55% bacosides, minimum 8-12 weeks This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Bacopa monnieri work?
- Bacosides A&B modulate cholinergic, serotonergic, GABAergic systems; antioxidant, dendritic proliferation; slow-onset cognitive enhancer requiring chronic dosing
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.